FDA Grants Fast Track Status to Affinia’s AFTX-201 Gene Therapy
Affinia Therapeutics has received Fast Track designation from the U.S. Food and Drug Administration for its investigational gene therapy candidate AFTX-201, a potential treatment for patients suffering from BAG3-associated dilated cardiomyopathy. The designation marks an important regulatory milestone for the biotechnology company as it advances therapies targeting severe cardiovascular diseases using adeno-associated virus (AAV) technology.
AFTX-201 is designed as a potentially best-in-class gene therapy aimed at addressing the underlying genetic cause of BAG3-associated dilated cardiomyopathy (DCM), a rare but serious condition that can lead to heart failure. The therapy delivers a fully human, full-length BAG3 gene using a proprietary viral capsid engineered by Affinia to improve gene delivery to heart tissue. According to the company, the engineered capsid allows effective cardiac transduction at doses that are approximately five to ten times lower than those typically required with conventional capsids such as AAV9 and AAVrh74.
The investigational therapy is currently being evaluated in the UPBEAT clinical trial, which is designed to assess the safety and effectiveness of AFTX-201 in individuals diagnosed with BAG3-related DCM. The treatment is administered as a one-time intravenous infusion, a format intended to simplify delivery and potentially provide long-lasting therapeutic benefits. In preclinical studies conducted in animal models of the disease, AFTX-201 was shown to increase BAG3 protein levels in the heart and fully restore cardiac function.
Dr. Hideo Makimura, Chief Medical Officer at Affinia Therapeutics, welcomed the regulatory recognition. He noted that the Fast Track designation, combined with the recent clearance of the company’s Investigational New Drug (IND) application by the FDA and the orphan drug designation granted by the European Medicines Agency, reinforces confidence in the therapy’s potential to address a significant unmet medical need.
Dilated cardiomyopathy remains one of the leading causes of heart failure among younger individuals and is a major reason for heart transplantation worldwide. For patients whose disease is driven by inherited mutations such as those affecting the BAG3 gene, traditional treatments often manage symptoms rather than addressing the underlying genetic defect.
Greg Ruf, founder and executive director of the DCM Foundation, emphasized the promise of gene therapy approaches for these patients. He highlighted that targeting the genetic root of the disease could provide meaningful benefits beyond current treatment options.
The Fast Track program is intended to accelerate the development and review of medicines for serious conditions where there is an unmet medical need. Companies granted the designation benefit from more frequent interactions with the FDA during development and may submit portions of their marketing applications for rolling review. If certain criteria are met, therapies with Fast Track status may also qualify for accelerated approval and priority review.
For Affinia Therapeutics, the designation may help shorten the development timeline for AFTX-201 as the company works to bring a potential new treatment option to patients living with BAG3-associated dilated cardiomyopathy.